Compare · ARVN vs NRIX

ARVN vs NRIX

Side-by-side comparison of Arvinas Inc. (ARVN) and Nurix Therapeutics Inc. (NRIX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARVN and NRIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NRIX is the larger of the two at $1.40B, about 3.3x ARVN ($423.0M).
  • NRIX has been more active in the news (15 items in the past 4 weeks vs 9 for ARVN).
  • ARVN has more recent analyst coverage (25 ratings vs 20 for NRIX).
MetricARVNNRIX
Company
Arvinas Inc.
Nurix Therapeutics Inc.
Price
-
-
Market cap
$423.0M
$1.40B
1M return
-
-49.63%
1Y return
-
-25.06%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2018
2020
News (4w)
9
15
Recent ratings
25
20
ARVN

Arvinas Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

NRIX

Nurix Therapeutics Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Latest ARVN

Latest NRIX